How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

982 results for

Endocrine Manifestations of HIV

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Primary & Secondary Prevention of CVD

in surrogate markers of inflammation and endothelial function but there have been no interventional studies to show that it can prevent CVD. 160-163 6.2.3 Human Immunodeficiency Virus (HIV) With the use of new and effective anti-viral therapy, the life expectancy of patients infected with HIV is almost approaching that of the general population. 164 CVD is becoming an important cause of mortality accounting for 6-11% of deaths. 164,165 HIV infected individuals of both gender, are at increased risk (...) Glycemic Load Glycemic Index Glucagon-like peptide–1 Glucose Tolerance Test Impaired Glucose Tolerance High Density Lipoprotein Cholesterol Human Immunodeficiency Virus Impaired Fasting Glucose Generally Recognized As Safe Ischaemic Heart Disease Low Carbohydrate Diets Low-Fat Diet Low Density Lipoprotein Cholesterol Komuniti Sihat Perkasa Negara LV LVH MHT MI MOH MSSM MUFA NCCFN NHMS NCD NCVD-ACS NGO NOAC NRT Left Ventricular Hypertrophy Left Ventricular Menopausal Hormone Therapy Ministry of Health

2017 Ministry of Health, Malaysia

102. Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

of the Fontan procedure, but its impact remains poorly defined in oth- er adults with CHD. 12 Genetic syndromes are commonly associated with CHD and may lead to unique endocrine and immunological complications. 13 Noncardiac causes of death in patients with Down syndrome include Al- zheimer disease, respiratory infections, stroke, DM, and seizures. 14 Cyanotic patients with CHD represent some of the most complex patients, with potential compli- cations affecting nearly all organ systems, including unique (...) liver disease IMMUNOLOGY/ INFECTIOUS DISEASE Protein-losing enteropathy Infective endocarditis Pneumonia Brain abscess HEMATOLOGY Secondary erythrocytosis/Iron (Cyanotic CHD) Thromboembolism Anemia ONCOLOGY Low-dose ionizing radiation and malignancy Hepatocellular carcinoma Age-appropriate cancer screening PSYCHOSOCIAL Depression Anxiety ENDOCRINE Thyroid Calcium hemostasis/Bone health Obesity/Metabolic syndrome Diabetes Dyslipidemia RENAL Chronic kidney disease Cardiorenal syndrome VASCULAR

2017 American Heart Association

103. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

to influence health behavior change, as described in the AHA Community Guide for Prevention, may have greater potential to reach both African American women and men and to shift the health behaviors and consequent cardiovascular risk of the entire population. Comorbidities Certain health conditions that predispose to CVDs are more common among African Americans than whites. Below, we highlight chronic kidney disease, sickle cell disease/sickle cell trait, and HIV, given their relatively higher prevalence

2017 American Heart Association

104. Syncope: Guideline For Evaluation and Management of Patients With

. PeripheralneuropathiesduetovitaminB 12 de?ciency, neurotoxic exposure, HIV and other infections, and porphyria areless common causes of neurogenic OH (240). It can be useful to consider referring patients with the following characteristics for autonomic evaluation: Parkinsonism (241,244–246) or other central nervous system features (247,248), peripheral neuropathies (240), underlying diseases known to be associated with a peripheral neuropathy (240,248), progressive autonomic dysfunction without central or peripheral nervous (...) /A Although patientswithSVTfrequently manifest

2017 American College of Cardiology

105. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

= cerebrovascu- lar; CVA = cerebrovascular accident; EL = evidence level; FH = familial hypercholesterolemia; FIELD = Secondary Endpoints from the Fenofibrate Intervention and Event Lowering in Diabetes trial; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk trial; HATS = HDL-Atherosclerosis Treatment Study; HDL-C = high- density lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; HHS = Helsinki Heart Study; HIV = human (...) immunodeficiency virus; HoFH = homozygous familial hypercholesterolemia; HPS = Heart Protection Study; HPS2-THRIVE = Treatment of HDL to Reduce the Incidence of Vascular Events trial; HR = hazard ratio; HRT = hormone replacement therapy; hsCRP = high-sensitivity CRP; IMPROVE- IT = Improved Reduction of Outcomes: Vytorin Efficacy International Trial; IRAS = Insulin Resistance Atherosclerosis Study; JUPITER = Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating

2017 American Association of Clinical Endocrinologists

107. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of NASPGHAN and ESPGHAN

, panhypopituitarism Abdominal surgery Necrotizing enterocolitis, intestinal atresia CF ¼ cystic ?brosis; CMV ¼ cytomegalovirus; HIV ¼ human immunode?ciency virus; PFIC¼ progressive familial intrahepatic cholestasis; PN ¼ parenteral nutrition; TJP ¼ tight-junction protein; TORCH ¼ Toxoplasma gondii, other viruses, rubella, cytomegalovirus, and herpes simplex virus. TABLE 3. Physical ?ndings in children with neonatal cholestasis Assessment of general health Ill appearance may indicate infection or metabolic disease (...) only articles published in English and involving human subjects. GRADES OF EVIDENCE Grades of evidence for each statement were based on the grading of the literature and were assigned using the American Association for the Study of Liver Diseases Practice Guidelines method: Grading of Recommendation Assessment, Development, and Evaluation workgroup with minor modifications (1). The strength of recommendations in the Grading of Recommendation Assessment, Development, and Evaluation system

2017 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

108. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update

First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update Comparative Effectiveness Review Number 184 First- and Second- Generation Antipsychotics in Children and Young Adults: Systematic Review Update e Comparative Effectiveness Review Number 184 First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 (...) of AHRQ or of the U.S. Department of Health and Human Services. None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application

2017 Effective Health Care Program (AHRQ)

109. The International Glossary on Infertility and Fertility Care

The International Glossary on Infertility and Fertility Care The International Glossary on Infertility and Fertility Care, 2017 Fernando Zegers-Hochschild, a G. David Adamson, b Silke Dyer, c Catherine Racowsky, d Jacques de Mouzon, e Rebecca Sokol, f Laura Rienzi, g Arne Sunde, h Lone Schmidt, i Ian D. Cooke, j Joe Leigh Simpson, k and Sheryl van der Poel l a University Diego Portales, Program of Ethics and Public Policies in Human Reproduction; Clinica las Condes, Unit of Reproductive (...) ‘fertilityawareness’togetherwithterminologiesusedinembryologyandandrologyhave Led by The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) in Partnership with the American Society for Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), International Federation of Fertility Societies, (IFFS), March of Dimes (MOD), African Fertility Society (AFS), Groupe Inter-africain d’Etude de Recherche et d’Application sur la Fertilit e (GIERAF), Asian Paci?c Initiative on Repro- duction (ASPIRE), Middle East

2017 Society for Assisted Reproductive Technology

110. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline

refractory to standard treatment, as well as for men taking glucocorticoid or opioid therapy and men with HIV infection if they have experienced weight loss (weak recommendation; low-quality evidence). 9. In men with erectile dysfunction and no other manifestations of testosterone deficiency syndrome, we suggest investigation only after a trial of phosphodiesterase type 5 (PDE-5) inhibitors has failed (weak recommendation; low-quality evidence). Treatment 10. We recommend that men with documented (...) testosterone + high LH/FSH Consider treatment or referral to TDS expert if clear manifestations of TDS but borderline biochemical levels Secondary hypogonadism (pituitary/hypothalamic) Low testosterone + normal LH/FSH Borderline low or low-normal testosterone (repeat for conrmation) Measure testosterone in morning (between 7 am and 11 am, or within 3 hours after waking) Clinical suspicion of TDS  Type II diabetes  Insulin resistance Metabolic syndrome  HIV-associated weight loss  Treatment

2015 CPG Infobase

111. Cabometyx (cabozantinib) - advanced renal cell carcinoma

Cabometyx (cabozantinib) - advanced renal cell carcinoma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 21 July 2016 EMA/664123/2016 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report CABOMETYX International non-proprietary name: cabozantinib Procedure No. EMEA/H/C/004163/0000 CHMP assessment report (...) CAP chest / abdomen / pelvis CHMP Committee for medicinal products for human use CI confidence interval CR complete response CRO contract research organization CT computerized tomography CTC circulating tumour cells CTCAE Common Terminology Criteria for Adverse Events DBP diastolic blood pressure DILI drug-induced liver injury DOR duration of response DRS disease-related symptoms (e)CRF (electronic) case report form CV% percent coefficient of variation EBRT external beam radiation therapy ECG

2016 European Medicines Agency - EPARs

112. Acute and Chronic Heart Failure Full Text available with Trip Pro

of the diagnostic workup, as they may offer specific therapeutic opportunities. Table 3.4 Aetiologies of heart failure ARVC = arrhythmogenic right ventricular cardiomyopathy; DCM = dilated cardiomyopathy; EMF = endomyocardial fibrosis; GH = growth hormone; HCM = hypertrophic cardiomyopathy; HES = hypereosinophilic syndrome; HIV/AIDS = human immunodeficiency virus/acquired immune deficiency syndrome; LV = left ventricular. Table 3.4 Aetiologies of heart failure ARVC = arrhythmogenic right ventricular (...) cardiomyopathy; DCM = dilated cardiomyopathy; EMF = endomyocardial fibrosis; GH = growth hormone; HCM = hypertrophic cardiomyopathy; HES = hypereosinophilic syndrome; HIV/AIDS = human immunodeficiency virus/acquired immune deficiency syndrome; LV = left ventricular. Many patients with HF and ischaemic heart disease (IHD) have a history of myocardial infarction or revascularization. However, a normal coronary angiogram does not exclude myocardial scar (e.g. by CMR imaging) or impaired coronary

2016 European Society of Cardiology

113. Dyslipidaemias Full Text available with Trip Pro

glomerular filtration rate GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GP general practitioner GWAS genome-wide association studies HAART highly active antiretroviral treatment HATS HDL-Atherosclerosis Treatment Study HbA1C glycated haemoglobin HeFH heterozygous familial hypercholesterolaemia HDL-C high-density lipoprotein cholesterol HF heart failure HHS Helsinki Heart Study HIV human immunodeficiency virus HMG-CoA hydroxymethylglutaryl-coenzyme A HPS Heart Protection (...) estimation CVD = cardiovascular disease; SCORE = Systemic Coronary Risk Estimation. a Class of recommendation. b Level of evidence. 3. Evaluation of laboratory lipid and apolipoprotein parameters Screening for dyslipidaemia is always indicated in subjects with clinical manifestations of CVD, in clinical conditions associated with increased risk for CVD and whenever risk factor screening is considered. In several clinical conditions, dyslipidaemia may contribute to an increased risk of developing CVD

2016 European Society of Cardiology

114. Praluent - alirocumab

Master cell bank mg Milligram MI Myocardial infarction min Minute mL Milliliter mm Millimeter mM Millimolar MMRM Mixed-effect model with repeated measures MMV Murine (Mouse) Minute Virus mOsm Milliosmole MRC-5 Human diploid lung cell MS Mass spectrometry N Newtons N Theoretical plate number N/A Not applicable Nab Neutralizing antibody NaCl Sodium chloride NCEP National Cholesterol Education Program ND Not detected NDS New drug submission NF National Formulary NGHC Non-glycosylated heavy chain NHP non (...) media that contain no components of animal or human origin. Multiple levels of control have been established throughout the alirocumab manufacturing process to minimize the risk of contamination of the finished product with adventitious viruses. Cell banks have been extensively tested for adventitious as well as endogenous agents. Relevant process steps have been investigated in virus validation studies. These studies provide evidence that the production process could remove adventitious virus

2015 European Medicines Agency - EPARs

115. Guidance on the clinical management of depressive and bipolar disorders, specifically focusing on diagnosis and treatment strategies

to the individual needs of those presenting for care. A primary motivation was to ensure that the guideline was engaging and useful to clinicians. For this reason a balance of academically focused and clinically focused experts in the field has been engaged in the writing of the guideline. Genuine involvement of clinicians of other disciplines, people with experience of mental illness, and carers has occurred to better balance the guideline. Human beings are complex biological systems, with mind as an emergent (...) dilemmas cannot be fully elucidated empirically because of significant ethical issues. An example of this is the evidence for safety of medications in pregnancy. Prospective human comparator trials face an ethical impasse, thus the evidence base is drawn largely from animal studies and association studies in humans. Sufficient power to identify rare adverse associations unfortunately only arises after many years of post-marketing surveillance. Similarly, investigating novel therapies for severe

2015 Royal Australian and New Zealand College of Psychiatrists

116. Guideline on the management of premature ovarian insufficiency

Guideline on the management of premature ovarian insufficiency 1 POI Guideline Development Group December 2015 Management of women with premature ovarian insufficiency Guideline of the European Society of Human Reproduction and Embryology 2 Disclaimer The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European (...) field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients. However

2015 European Society of Human Reproduction and Embryology

117. Dementia

early (the third decade) or very late (ninth decade). Rarer causes of dementia include: Parkinson’s disease (PD) dementia — subcortical dementia occurs in up to 50% of people with PD. Motor symptoms of PD appear many years before dementia. For further information, see the CKS topic on . Progressive supranuclear palsy. Huntington’s disease. Prion disease (such as Creutzfeldt-Jakob disease [CJD]). Normal pressure hydrocephalus. Chronic subdural haematoma. Benign tumours. Metabolic and endocrine (...) disorders (such as chronic hypocalcaemia and recurrent hypoglycaemia). Vitamin deficiencies (such as B12 and thiamine deficiency). For further information, see the CKS topic on . Infections (such as HIV infection and syphilis). For further information, see the CKS topic on . [ ; ; ; ; ; ; ] Risk factors What are the risk factors? Risk factors for dementia include: Age — older age is the strongest risk factor for dementia. Mild cognitive impairment — 50% of people with mild cognitive impairment

2019 NICE Clinical Knowledge Summaries

118. Developmental rheumatology in children. Scenario: Hypermobility in children

dysplasia, bony manifestation of endocrine or renal abnormalities) [ ]. There may be an association with pathologic bow legs and early osteoarthritis. Surgery may be necessary if the condition does not spontaneously resolve or there is extreme angulation [ ]. Scenario: Clumsy child Scenario: Clumsy child From birth to 16 years. Clumsy child When should I consider referring a clumsy child? Management in the community (for example by a physiotherapist with paediatric expertise) is usually appropriate (...) or young person with: Atypical symptoms. Worsening symptoms. Unremitting pain; night pain; thoracic pain. Non-mechanical pain. Abnormal loss or deterioration of function. Significant loss of movement. Gait disturbance. Significant lower limb asymmetry. TB, cancer, HIV/AIDS, steroid use, multiple fractures. Skin changes, for example, cafe au lait, psoriasis, bruising. Paediatric Musculoskeletal Matters ( ) is a resource for clinicians working with children and young people. It aims to facilitate early

2019 NICE Clinical Knowledge Summaries

119. Developmental rheumatology in children. Scenario: In-toeing gait in children

dysplasia, bony manifestation of endocrine or renal abnormalities) [ ]. There may be an association with pathologic bow legs and early osteoarthritis. Surgery may be necessary if the condition does not spontaneously resolve or there is extreme angulation [ ]. Scenario: Clumsy child Scenario: Clumsy child From birth to 16 years. Clumsy child When should I consider referring a clumsy child? Management in the community (for example by a physiotherapist with paediatric expertise) is usually appropriate (...) or young person with: Atypical symptoms. Worsening symptoms. Unremitting pain; night pain; thoracic pain. Non-mechanical pain. Abnormal loss or deterioration of function. Significant loss of movement. Gait disturbance. Significant lower limb asymmetry. TB, cancer, HIV/AIDS, steroid use, multiple fractures. Skin changes, for example, cafe au lait, psoriasis, bruising. Paediatric Musculoskeletal Matters ( ) is a resource for clinicians working with children and young people. It aims to facilitate early

2019 NICE Clinical Knowledge Summaries

120. Developmental rheumatology in children. Scenario: Heel pain in children

dysplasia, bony manifestation of endocrine or renal abnormalities) [ ]. There may be an association with pathologic bow legs and early osteoarthritis. Surgery may be necessary if the condition does not spontaneously resolve or there is extreme angulation [ ]. Scenario: Clumsy child Scenario: Clumsy child From birth to 16 years. Clumsy child When should I consider referring a clumsy child? Management in the community (for example by a physiotherapist with paediatric expertise) is usually appropriate (...) or young person with: Atypical symptoms. Worsening symptoms. Unremitting pain; night pain; thoracic pain. Non-mechanical pain. Abnormal loss or deterioration of function. Significant loss of movement. Gait disturbance. Significant lower limb asymmetry. TB, cancer, HIV/AIDS, steroid use, multiple fractures. Skin changes, for example, cafe au lait, psoriasis, bruising. Paediatric Musculoskeletal Matters ( ) is a resource for clinicians working with children and young people. It aims to facilitate early

2019 NICE Clinical Knowledge Summaries

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>